Navigation Links
Neptune Technologies decided not to re-price options
Date:9/12/2008

LAVAL, QC, Sept. 12 /PRNewswire-FirstCall/ - The Board of Directors of Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB) decided not to re-price any options including the previously announced 850,000 options owned by officers and directors.

About Neptune Technologies

Neptune researches and develops proprietary bioactive ingredients and products for nutraceutical and pharmaceutical applications and is sponsoring clinical research to demonstrate the therapeutic benefits in various medical indications. The Company patents its intellectual property, protects its industrial secrets and innovations and continuously expands its intellectual property portfolio. Neptune has already obtained many regulatory approvals allowing commercialization of its products in various geographic markets and has filed for and is expecting additional approvals. Neptune continues to strongly support its strategic development plan to form partnerships with worldwide leaders in the nutraceutical industries. Neptune has signed agreements with Nestle and Yoplait, worldwide leading food manufacturers, and paved its entrance into the global functional food market.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.


'/>"/>
SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
2. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
3. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
4. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
5. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
6. Neptune Technologies expands into medicinal markets in Asia Pacific
7. Neptune Technologies receives GRAS notification in the United States
8. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
9. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
10. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
11. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... Litmus Health , ... its full advisory board. The board comprises leaders spanning business, technology, academia, and ... former VP of Engineering, to Chief Technology Officer. Crooks will lead strategy and ...
(Date:7/20/2017)... 2017   KCNQ2 Cure Alliance  and ... today announced that they have completed the first ... implicated in KCNQ2 epileptic encephalopathy. They also report ... case involving an additional KCNQ2 genetic mutation. ... Pairnomix entered into a collaboration to further explore ...
(Date:7/18/2017)... San Diego, CA (PRWEB) , ... July 18, ... ... pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of ... system. The new biosensor chip enables researchers to study the kinetics of polyhistidine-tagged ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... from the United States Patent and Trademark Office for its Patent Applications 14/858,857 ... Trademark Office’s allowances of these patent applications further expand the protection of G-CON’s ...
Breaking Biology Technology:
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), ... published by MarketsandMarkets, the market is expected to be worth USD 18.98 billion ... Continue Reading ... ...      (Logo: ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
Breaking Biology News(10 mins):